title: Effects of 12 months of GH treatment on cortical and trabecular bone content of IGFs and OPG in adults with acquired GH deficiency: a double-blind, randomized, placebo-controlled study.
abstract: To investigate the effects of 12 months of GH treatment on cortical and trabecular bone content of IGFs, iliac crest bone biopsies were obtained from 25 patients with GH deficiency (9 women and 16 men; ages, 21-61 yr; mean, 46 yr) who were randomized to sc injections with GH (2 IU/m(2).d) or placebo for 12 months. Levels of IGF-I, IGF-II, IGF binding protein (IGFBP)-3, IGFBP-5, osteocalcin, OPG, RANKL, and total protein were determined in extracts obtained after EDTA and guanidine hydrochloride extraction. Calcium was determined after HCl hydrolysis. Comparing changes during GH or placebo treatment, significant increases were observed during GH substitution for cortical and trabecular bone content of IGF-I [mean difference vs. placebo (mean +/- SEM), 97 +/- 30 and 72 +/- 38%] and OPG (mean difference vs. placebo, 109 +/- 59 and 51 +/- 19%). Also, a significant decline was found for cortical osteocalcin (mean difference vs. placebo, -49 +/- 22%) during GH treatment. In conclusion, our results indicate that long-term GH treatment increases the accumulation of IGF-I and OPG in cortical and trabecular bone in patients with GH deficiency, and this may in turn lead to an increase in bone mass and improved skeletal biomechanical competence.
authors.affiliation: Department of Endocrinology, National University Hospital, N-0027 Oslo, Norway. thor.ueland@klinmed.uio.no
authors.forename: Thor
authors.initials: T
authors.lastname: Ueland
authors.forename: J
authors.initials: J
authors.lastname: Bollerslev
authors.forename: A
authors.initials: A
authors.lastname: Flyvbjerg
authors.forename: T B
authors.initials: TB
authors.lastname: Hansen
authors.forename: N
authors.initials: N
authors.lastname: Vahl
authors.forename: L
authors.initials: L
authors.lastname: Mosekilde
mesh_terms: D000328:Adult; D001842:Bone and Bones / Q000187:drug effects* / Q000378:metabolism*; D003677:Deficiency Diseases / Q000188:drug therapy* / Q000378:metabolism*; D004311:Double-Blind Method; D005260:Female; D006023:Glycoproteins / Q000378:metabolism*; D019382:Human Growth Hormone / Q000172:deficiency* / Q000627:therapeutic use*; D006801:Humans; D008297:Male; D008875:Middle Aged; D015675:Osteocalcin / Q000378:metabolism; D053244:Osteoprotegerin; D018160:Receptors, Cytoplasmic and Nuclear / Q000378:metabolism*; D018124:Receptors, Tumor Necrosis Factor; D013002:Somatomedins / Q000378:metabolism*; D013997:Time Factors
chemical_list: D006023:Glycoproteins; D053244:Osteoprotegerin; D018160:Receptors, Cytoplasmic and Nuclear; D018124:Receptors, Tumor Necrosis Factor; D013002:Somatomedins; C506030:TNFRSF11B protein, human; D015675:Osteocalcin; D019382:Human Growth Hormone